Clinical Trials Directory

Trials / Completed

CompletedNCT03558854

Evaluation of Effectiveness of Acetylsalicylic Acid on Markers of Vascular Dysfunction in Scleroderma Patients

Evaluation of Effectiveness of Acetylsalicylic Acid on Markers of Vascular Dysfunction in Patients With Systemic Sclerosis

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
70 (actual)
Sponsor
Federal University of São Paulo · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

Systemic sclerosis is a chronic autoimmune disease characterized by vascular changes in the microcirculation (small blood vessels) and progressive fibrosis of the skin and internal organs. It is believed that vascular changes, expressed early by the Raynaud phenomenon, precede fibrosis and organic dysfunction. There is no available treatment that reverses the vascular damage caused by the disease to the moment, although there are several medications recommended for the relief of manifestations due to vascular injury. Acetylsalicylic acid (ASA) is one of the medications that can be used for the treatment of vascular injury present in systemic sclerosis, but still without a fully proven benefit. This study aims to evaluate the effectiveness of ASA on microcirculation alterations in patients with systemic sclerosis by performing three exams: periungual panoramic capillary microscopy, videocapillaroscopy and laser Doppler imaging. In addition, a blood sample will be collected for dosing the following vascular lesion markers: endothelin-1, von Willebrand factor, thromboxane, and platelet-derived, endothelial-derived and monocyte-derived microparticles.

Conditions

Interventions

TypeNameDescription
DRUGAcetylsalicylic acidPatients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
DRUGPlacebo oral capsulePatients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks

Timeline

Start date
2018-08-28
Primary completion
2021-09-02
Completion
2021-10-26
First posted
2018-06-15
Last updated
2021-12-01

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT03558854. Inclusion in this directory is not an endorsement.